All News

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a significant contract by a new UK-based biotech client. This client sits at the forefront of AI-driven design and development of novel therapies across various therapeutic areas. The project involves the use of our...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, would like to update the market on a change to the composition of its board.   Dr Christophe Chassagnole will step down as a Director of the Company and as Chief Scientific Officer (CSO), effective 31 May 2024, to pursue other career opportunities.  Dr Chassagnole...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, provides the following update on current trading.   Despite having a strong pipeline of potential new business, several large contracts have taken longer than expected to be signed and as a result the Company’s total income for the financial year ending 30 June 2024 (“FY24”)...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, recently provided a brief update in-line with its interim results via Investor Meet Company and has updated its website with the presentation.   The presentation and Q&A from the meeting are now available at the Company’s website: https://www.physiomics.co.uk/portfolio-item/investor-presentation-interim-results-and-company-update/     Enquiries:   Physiomics plc Dr Jim Millen, Non-Executive Chairman, +44 (0)1235...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a substantial new contract by an existing large pharma client.  The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling in the field of DNA damage/ repair field and will help inform clinical dose and scheduling decisions. The value...